Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Expenses: 2021-2024

Historic Operating Expenses for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to $377.9 million.

  • Immunocore Holdings' Operating Expenses rose 24.97% to $110.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.0 million, marking a year-over-year increase of 16.65%. This contributed to the annual value of $377.9 million for FY2024, which is 22.69% up from last year.
  • According to the latest figures from FY2024, Immunocore Holdings' Operating Expenses is $377.9 million, which was up 22.69% from $308.0 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' Operating Expenses registered a high of $377.9 million during FY2024, and its lowest value of $211.1 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $308.0 million (2023), whereas its average is $303.7 million.
  • Data for Immunocore Holdings' Operating Expenses shows a peak YoY spiked of 36.92% (in 2023) over the last 5 years.
  • Over the past 4 years, Immunocore Holdings' Operating Expenses (Yearly) stood at $211.1 million in 2021, then rose by 6.59% to $225.0 million in 2022, then soared by 36.92% to $308.0 million in 2023, then increased by 22.69% to $377.9 million in 2024.